NCT04761978

Withdrawn

Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic D...

University Hospital, Lille Source

University Hospital, Lille

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

NI_2021_01

Study Type

observational

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

September 1, 2021

Actual (reported)

Primary Completion

September 1, 2022

Actual (reported)

Study Completion

September 1, 2022

Actual (reported)

Brief Summary

The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: September 1, 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
February 15, 2021
Actual (reported)
First Posted
February 21, 2021
Actual (reported)
Study Start
September 1, 2021
Actual (reported)
Primary Completion
September 1, 2022
Actual (reported)
Study Completion
September 1, 2022
Actual (reported)

Last Updated: May 22, 2026
Status Verified: May 2026
Last Update Submitted: May 20, 2026

Conditions

Dermatitis, Atopic

Keywords

EffectivenessSafetyJAK inhibitorsAtopic dermatitisAdults

Outcome Measures

Primary Outcomes (1)

reduction in Eczema Area and Severity Index (EASI)
At 3 months

Secondary Outcomes (6)

SCORing Atopic Dermatitis (SCORAD)
at baseline and at 3 months
Investigator's Global Assessment (IGA)
at baseline and at 3 months
Dermatology Life Quality Index (DLQI)
at baseline and at 3 months
patient-reported pruritus score from 0 to 10
at baseline and at 3 months
patient-reported sleep loss from 0 to 10
at baseline and at 3 months
+1 more secondary outcomes

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients assessed by French members of the Groupe de Recherche sur l'Eczema Atopique.

You may qualify if:

Adults

Sponsors & Collaborators

University Hospital, Lille
Otherlead

Study Sites (1)

Hop Claude Huriez Chu Lille

Lisle-sur-Tarn, 59037, France

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

Delphine Staumont-Salle, MD,PhD
University Hospital, Lille
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 15, 2021

First Posted

February 21, 2021

Study Start

September 1, 2021

Actual (reported)

NCT05318300

Evaluation of an Adapted Formula on Atopic Dermatitis.

Not ApplicableUnknown

NCT05639738

Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD

Not ApplicableTerminated

NCT04553224

Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis

Not ApplicableCompleted

NCT04728269

Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis

Not ApplicableCompleted

NCT05833880

Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis

Completed

NCT03684343

Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age

Not ApplicableTerminated

moderate to severe atopic dermatitis

treated by JAK inhibitors between december 2020 and september 2021

inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy

ineligibility to French ongoing clinical trials

You may not qualify if:

Children
mild atopic dermatitis
eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy
eligibility to French ongoing clinical trials
patients' opposition for the use of their records
follow up \<3 months

Contact the study team to confirm eligibility.

Primary Completion

September 1, 2022

Actual (reported)

Study Completion

September 1, 2022

Actual (reported)

Last Updated

May 22, 2026

Record last verified: 2026-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04761978
Data provider: ClinicalTrials.gov
Source updated: 2026-05-22
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:17 UTC

Locations

FR(1)

Study Stopped

Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations